Impact of left ventricular unloading timing on clinical outcomes in venoarterial extracorporeal membrane oxygenation: an updated systematic review and meta-analysis

左心室卸载时机对静脉-动脉体外膜肺氧合临床结局的影响:一项更新的系统评价和荟萃分析

阅读:2

Abstract

BACKGROUND: The optimal timing of left ventricular unloading in patients with cardiogenic shock receiving venoarterial extracorporeal membrane oxygenation therapy remains controversial. This systematic review evaluated the latest evidence on the impact of left ventricular unloading timing in patients with cardiogenic shock receiving venoarterial extracorporeal membrane oxygenation. METHODS: The PubMed, Embase and Cochrane Library databases were searched from inception to February 2025. The identified studies were screened based on predefined inclusion and exclusion criteria, and eligible studies were subjected to quality assessment and data extraction. Heterogeneity testing and meta-analysis were performed using Review Manager software version 5.4. RESULTS: Eight studies involving 2,117 patients (proactive unloading, 1,338; passive unloading, 779) were included in the meta-analysis, which revealed no statistically significant differences in extracorporeal membrane oxygenation weaning rates (relative risk = 1.06, 95% confidence interval: 0.87-1.28; P = 0.59), in-hospital mortality (relative risk = 0.95, 95% confidence interval: 0.86-1.04; P = 0.28), or 30-day all-cause mortality (relative risk = 0.75, 95% confidence interval: 0.52-1.10; P = 0.14) between the proactive and passive unloading groups. However, the risks of sepsis (relative risk = 0.79, 95% confidence interval: 0.64-0.96; P = 0.02) and abdominal complications (relative risk = 0.67, 95% confidence interval: 0.46-0.96; P = 0.03) were lower following proactive unloading than following passive unloading. CONCLUSION: Compared to passive left ventricular unloading, proactive left ventricular unloading did not confer significant benefits in terms of extracorporeal membrane oxygenation weaning success or short-term survival outcomes, but was associated with reduced risks of sepsis and abdominal complications. REGISTRATION: The review protocol was registered in PROSPERO (ID: CRD42024499028).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。